Cargando…

Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF

Diagnosing interstitial lung disease (ILD) can be a challenging process. New biomarkers may support diagnostic decisions. Elevated serum progranulin (PGRN) levels have been reported in liver fibrosis and dermatomyositis-associated acute interstitial pneumonia. Our aim was to assess the role of PGRN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tóth, Nóra Melinda, Müller, Veronika, Nagy, Tamás, Polivka, Lőrinc, Horváth, Péter, Bohács, Anikó, Eszes, Noémi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252558/ https://www.ncbi.nlm.nih.gov/pubmed/37298130 http://dx.doi.org/10.3390/ijms24119178

Ejemplares similares

ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF
por: Durheim, Michael T, et al.
Publicado: (2020)

Exploring the common pathophysiological links between IPF, SSc-ILD and post-COVID fibrosis
por: Swarnakar, Rajesh, et al.
Publicado: (2022)

Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry
por: Nagy, Tamas, et al.
Publicado: (2022)

Remdesivir in Solid Organ Recipients for COVID-19 Pneumonia
por: Fesu, Dorottya, et al.
Publicado: (2022)

Development of the ATAQ-IPF: a tool to assess quality of life in IPF
por: Swigris, Jeffrey J, et al.
Publicado: (2010)

Recommendations on treatment for IPF
por: Behr, Jürgen, et al.
Publicado: (2013)

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
por: Jo, Helen E., et al.
Publicado: (2019)

Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox
por: Nagy, Alexandra, et al.
Publicado: (2022)

Investigation of key autophagy-and mitophagy-related proteins and gene expression in BALF cells from patients with IPF and RA-ILD
por: Vasarmidi, Eirini, et al.
Publicado: (2018)

Highlights of HRCT imaging in IPF
por: Sverzellati, N
Publicado: (2013)

IPF - Idiopathic Pulmonary Fibrosis
Publicado: (2019)

The role of neutrophils in the pathogenesis of IPF
por: Jegal, Yangjin
Publicado: (2022)

Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease
por: Fesu, Dorottya, et al.
Publicado: (2023)

Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
por: de Andrade, Joao A., et al.
Publicado: (2022)

Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior
por: Khine, Ngu, et al.
Publicado: (2020)

IPF clinical trial design and endpoints
por: Nathan, Steven D., et al.
Publicado: (2014)

Mitochondrial Quality Control in COPD and IPF
por: Hara, Hiromichi, et al.
Publicado: (2018)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
por: Barratt, Shaney L., et al.
Publicado: (2018)

The Role of Immunity and Inflammation in IPF Pathogenesis
por: Butler, Marcus W., et al.
Publicado: (2018)

Senescent Cells in IPF: Locked in Repair?
por: Meiners, Silke, et al.
Publicado: (2020)

IPF in Saudi Arabia: Lessons for all
por: Nathan, Steven D.
Publicado: (2020)

Microbiota and IPF: hidden and detected relationships
por: Fabbrizzi, Alessio, et al.
Publicado: (2021)

Radiological and Physiological Predictors of IPF Mortality
por: Kishaba, Tomoo, et al.
Publicado: (2021)

Moving senolytics closer to the clinic in IPF
por: Kramer, Daniel, et al.
Publicado: (2023)

CA 19-9 serum levels in patients with end-stage idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs): Correlation with functional decline
por: Balestro, Elisabetta, et al.
Publicado: (2020)

Serological findings following the second and third SARS‐CoV‐2 vaccines in lung transplant recipients
por: Bárczi, Enikő, et al.
Publicado: (2022)

Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013)

The Role of Cardiopulmonary Exercise Test in IPF Prognosis
por: Triantafillidou, Christina, et al.
Publicado: (2013)

Opioids: an unexplored option for treatment of dyspnea in IPF
por: Kohberg, Charlotte, et al.
Publicado: (2016)

Evolving Perspectives on Innate Immune Mechanisms of IPF
por: Ishikawa, Genta, et al.
Publicado: (2021)

IPF-Acute Exacerbations: Advances and Future Perspectives
por: Papiris, Spyros A., et al.
Publicado: (2022)

IPF Respiratory Symptoms Management — Current Evidence
por: Janowiak, Piotr, et al.
Publicado: (2022)

Epigenetic regulation of IPF fibroblast phenotype by glutaminolysis
por: Xiang, Zheyi, et al.
Publicado: (2022)

Histopathological evaluation of autopsy cases with isolated pulmonary fat embolism (IPFE): is cardiopulmonary resuscitation a main cause of death in IPFE?
por: Turkmen Samdanci, Emine, et al.
Publicado: (2019)

Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival
por: Barczi, Eniko, et al.
Publicado: (2020)

The pathogenesis of COPD and IPF: Distinct horns of the same devil?
por: Chilosi, Marco, et al.
Publicado: (2012)

Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
por: Antoniu, Sabina A
Publicado: (2012)

Regulation of TERRA on telomeric and mitochondrial functions in IPF pathogenesis
por: Gao, Yulin, et al.
Publicado: (2017)

Imaging Review of the Lung Parenchymal Complications in Patients with IPF
por: Baratella, Elisa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6obpkdnidhvsg8rt17tphtv7rv